Skip to content

5% or 2% dextrose infusion, prevention of postoperative nausea and vomiting after laparoscopic surgery

5% or 2% dextrose infusion, which is superior for the prevention of postoperative nausea and vomiting after laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/12/047977
Enrollment
120
Registered
2022-12-08
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K807- Calculus of gallbladder and bile duct without cholecystitis

Interventions

Intervention1: infusion of 5% dextrose: 5% dextrose infusion will be prepared by adding 50ml of 50% dextrose in 450ml of ringer lactate and will be started at the rate of 3ml/kg/hour 30 mins prior to

Sponsors

Dr J Naveen kumar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I and II patients Age between 18-65 years Patients undergoing elective laparoscopic surgery under general anesthesia

Exclusion criteria

Exclusion criteria: Patients with physical status III or more Patients with history of PONV, smoking, motion sickness, diabetes, hypertension, cardiac, renal or hepatic dysfunction, pregnant or menstruating patients, obesity (BMI > 30 kg/m2) and prolonged surgery ( >2 hours) Subjects who could not use the verbal descriptive scale (VDS) Patients receiving an antiemetic agent within 24 hours before surgery or cases where complications occurred during surgery.

Design outcomes

Primary

MeasureTime frame
postoperative nausea and vomiting incidence and intensityTimepoint: postoperative nausea and vomiting incidence and intensity will be measured at PACU arrival at 30,60,90,120 and at 6,12,24hrs after surgery

Secondary

MeasureTime frame
requirement of rescue antiemetic(single dose and repeated dose)Timepoint: time of oral acceptance of feed, blood sugar level will be measured using a point of device immediately before starting study fluid infusion, before induction, intraoperatively after induction followed by 60mins intervel and postoperatively at PACU arrival and at 2 and 6 hrs. postoperatively those who will develop nausea or vomiting will receive 0.1mg/kg iv ondansetron

Countries

India

Contacts

Public ContactDr poonam hannurkar

Dr. d y patil medical college, hospital and research centre,

drphannurkar@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026